Skip to main content
Press release

Actis invests $48 million in Indian pharma company

22 October 2013
Email Actis

Actis today announced its investment of $48 million, for a significant stake in Symbiotec Pharmalab Limited (“Symbiotec”).

Over the past decade, Symbiotec has grown to become a leading specialist producer of steroid- hormone active pharmaceutical ingredients (APIs). These active ingredients are used by Symbiotec’s 200+ customers, which include both large multinationals as well as generic pharma companies, to manufacture high quality medications, including treatments for inflammation, asthma, dermatology, immune functions, and infertility.

Today Symbiotec is India’s leading steroid-hormone active ingredient producer, and the second largest player in Asia. With the largest number of US Food and Drug Administration approved Active Pharmaceutical Ingredient plants in the world, India is well placed to maintain its global market share by producing high-end, difficult-to-manufacture molecules and drug classes.

Commenting on the investment, JM Trivedi, Partner and Head of South Asia at Actis, said: “Symbiotec is the leading Indian manufacturer of steroids-hormone APIs, a specialised pharmaceutical segment. With its US FDA approved facilities and high quality products with Asian cost manufacturing advantages, it is on track to become a leading global player. We look forward to working with Anil Satwani and his team to build on Symbiotec’s success to date.”

Anil Satwani, founder and promoter at Symbiotec said: “We are delighted to welcome Actis as a partner, one that understands our niche business and brings deep healthcare sector expertise. With their help, we look forward to becoming a global force in the steroid-hormone segment, and writing the next chapter in the company’s growth story, ensuring we maintain the very best corporate governance, financial reporting, environmental and social practices as well as identifying and unlocking new markets.”

IDFC Capital acted as exclusive adviser to Symbiotec on the deal.

Sign up to the street view for the latest news and insights